Starpharma Holdings Ltd. | Ownership
Companies that own Starpharma Holdings Ltd.
Allan Gray Australia Pty Ltd.
49,041,042
13.24%
0
1.53%
08/23/2017
FIL Investment Management (Hong Kong) Ltd.
22,276,669
6.01%
-862,003
0.09%
06/01/2018
The Vanguard Group, Inc.
8,697,043
2.35%
362
0%
07/31/2018
Allianz Global Investors Asia Pacific Ltd.
8,008,286
2.16%
-383,100
0.1%
05/31/2018
Manulife Asset Management (Hong Kong) Ltd.
2,912,051
0.79%
2,912,051
0.06%
12/31/2017
Vanguard Investments Australia Ltd.
2,616,476
0.71%
205,643
0.01%
07/31/2018
Norges Bank Investment Management
1,702,594
0.46%
196,385
0%
12/31/2017
Tiburon Partners LLP
1,643,796
0.44%
0
1.61%
07/31/2018
FIL Investment Management (Australia) Ltd.
898,489
0.24%
-625,200
0.01%
06/01/2018
FIL Investment Advisors (UK) Ltd.
885,091
0.24%
-3,475,258
0%
06/01/2018
| Address |
4-6 Southampton Crescent
Abbotsford Victoria (VIC) 3067
Australia
|
|
Employees
|
- |
| Website |
http://www.starpharma.com |
| Updated |
07/08/2019 |
| Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. |
